Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103778 · ClinicalTrials.gov registry record · Phase 4
Pilot Study of Velcade® in IgA Nephropathy
A Phase 4 study, sponsored by The Rogosin Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01103778 is a Phase 4 study that has completed, run by The Rogosin Institute. The registered enrollment target is 11 participants.
The verdict
NCT01103778, a Phase 4 study, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preservation of renal function, partial responders, relapse rate, and to study mechanistic assays to predict remission.
Interventions
- DRUG Bortezomib (Velcade®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-07 |
| Est. Completion | 2017-04-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103778
The ClinicalTrials.gov registry entry for NCT01103778 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bortezomib (Velcade®) is the first listed.
NCT01103778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103778 about?
NCT01103778 is a clinical study titled "Pilot Study of Velcade® in IgA Nephropathy". The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy. The secondary objectives are to assess clinical outcomes relating to safety and efficacy, such as infection, malignancy, preser...
What is the current status of trial NCT01103778?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2010-07. Estimated completion is 2017-04-17.
What interventions are being tested in trial NCT01103778?
The interventions under investigation include: Bortezomib (Velcade®) (DRUG).
Who is sponsoring clinical trial NCT01103778?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.